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Maternal milk has been recognized by public
health ofﬁcials as the most beneﬁcial source
of nourishment during infancy. The U.S.
Department of Health and Human Services,
through the Healthy People 2010 objectives,
has set a target goal of early postpartum
breast-feeding rates of 75% by the year 2010
(1). This emphasis on breast-feeding is moti-
vated by the fact that breast milk provides
the most complete form of nutrition for
infants, imparts increased protection from
diseases, and improves maternal health
through the physiologic responses associated
with lactation. However, potential risks asso-
ciated with breast-feeding also need to be
factored into the overall public health assess-
ment when women are encouraged to breast-
feed their newborn infants (2). For example,
through the process of breast-feeding, it is
possible for the mother to transfer to the
suckling infant potentially toxic chemicals to
which the mother has previously been
exposed. Due to the rapid mental and physi-
cal changes that are taking place, neonates
can be more susceptible to adverse effects
resulting from chemical exposures (2,3).
Historically, the study of prescription
drugs has provided a basis for understanding
the governing principles behind transfer of
chemicals through breast milk (4). These
factors can be separated into two broad cate-
gories: maternal characteristics and chemical
characteristics (5,6). Maternal characteristics
include the degree of maternal exposure,
physiology of the mother, maternal age, and
parity (number of pregnancies). Chemical
characteristics refer to aspects of the com-
pound that affect its ability to be taken up in
milk, such as the lipid solubility, degree of ion-
ization, molecular weight, and ability to bind
to maternal blood and/or milk components.
Maternal Factors and
Physiologic Status
The most critical maternal factor in determin-
ing chemical dose to the infant is the extent
and pattern of maternal chemical exposure. In
the case of prescription drugs, dosage and fre-
quency of ingestion are easily determined. For
unintentional chemical exposures, whether
they are environmental or occupational, the
route and extent of exposure are often difﬁ-
cult to determine. It is necessary to recreate
occupational, environmental, and even
dietary inﬂuences to uncover possible sources
of chemical exposure. Methylmercury (6) and
polychlorinated biphenyls (PCBs) (7,8) are
environmental contaminants that are concen-
trated in ﬁsh. In populations where ﬁsh is a
large part of the diet, maternal consumption
can determine the infant’s exposure level to
these toxins. 
Maternal physiology, such as adipose tis-
sue levels, age, parity, milk composition and
volume, and breast-feeding patterns, also
inﬂuence the amount of chemical passed to
the infant (9–11). Lipophilic chemicals are
partitioned into fatty tissue and can be stored
there for long periods of time due to low
blood ﬂow in these tissues and limited tissue
mass turnover. However, in the case of sud-
den weight loss, these chemicals can be
released back into circulation, allowing them
to be taken up into fat of the mammary
gland. Maternal age and parity are also related
to the transfer of chemicals in breast milk.
Milk levels of dioxins would be likely to
increase with maternal age, due to increases in
extent of body fat, where the chemical accu-
mulates. Conversely, milk levels of dioxins
have been shown to decrease with increasing
number of pregnancies (12–14).
Milk composition is quite variable, dif-
fering over the course of lactation as well as
within individual breast-feeding sessions
(15,16). Studies have shown human milk to
contain high levels of protein (10%) in the
ﬁrst postpartum week, while lipid (fat) levels
are relatively low (1%). However, the fat lev-
els in mature milk increase (4%) and protein
levels decrease (1%). Because the lowest rela-
tive lipid concentrations in milk occur dur-
ing the ﬁrst week after birth, when the milk
is colostrum, transfer of highly lipophilic
chemicals would be less likely to occur dur-
ing early lactation. Conversely, because pro-
tein content is highest during this time,
chemicals with high afﬁnity for proteins may
be more prone to be transported to the milk.
Figure 1 shows the increase in fat content of
human milk from a group of subjects over
the course of lactation (17). Fat content
increased significantly during the first 21
days of lactation, with a 40% increase in the
first week, a constant level from 21 to 42
days, and a statistically insigniﬁcant increase
to day 84, most likely due to decreased num-
bers of subjects in the study. Within feeding
sessions, milk composition is also quite vari-
able (18). For example, milk at the start of a
feeding session contains less fat than milk at
the end (1–2% vs. 4–6%). These changes in
milk composition directly affect the amount
of chemical transferred through milk due to
possible interactions between milk compo-
nents and the chemical of interest (19). 
Chemical Characteristics
The aforementioned physical factors,
together with chemical characteristics such as
the polarity of the compound, determine
chemical transfer in milk. Figure 2 shows the
uptake of benzene (a lipophilic chemical)
into milk versus the protein and triglyceride
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Factors controlling the transfer of potentially toxic chemicals in the breast milk of nursing moth-
ers include both chemical characteristics, such as lipophilicity, and physiologic changes during
lactation. Physiologically based pharmacokinetic (PBPK) models can aid in the prediction of
infant exposure via breast milk. Benefits of these quantitative models include the ability to
account for changing maternal physiology and transfer kinetics, as well as the chemical-specific
characteristics, in order to produce more accurate estimates of neonatal risk. A recently developed
PBPK model for perchlorate and iodide kinetics in the lactating and neonatal rat demonstrates
the utility of PBPK modeling in predicting maternal and neonatal distribution of these two com-
pounds. This model incorporates time-dependent changes in physiologic characteristics and
includes interactions between iodide and perchlorate that alter the distribution and kinetics of
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Mini-Monographconcentration of milk. The uptake of the
organic chemical is directly related to milk fat
content. However, there is no correlation
between the amount of this hydrocarbon and
the milk protein level. Nonpolar compounds
are easily transported across lipid membranes
and can be retained in milk fat due to their
lipophilic characteristics (21). Ionic com-
pounds are not expected to partition into
milk in this manner. Some weak bases can
preferentially enter the milk as a result of the
pH gradient that exists between the blood
(pH = 7.4) and milk (pH = 8), whereas other
ionic compounds are transported into the
milk via active uptake mechanisms (22,23). 
Additional chemical-speciﬁc characteris-
tics that help to determine the extent to
which a compound will enter milk are mole-
cular weight, maternal metabolism before
transfer to the mammary gland, and protein
binding in the plasma or mammary gland. In
general, smaller compounds are transferred
into mammary tissue more easily than those
with high molecular weights (> 200 g/mol)
(24). Some chemicals are metabolized within
the mammary gland, resulting in lower levels
of the original substance available for transfer
to the infant (25). When chemicals are
bound to protein in milk, they can accumu-
late, resulting in higher chemical concentra-
tions. However, if protein binding takes
place in the plasma, less chemical is available
to enter the mammary gland, thereby reduc-
ing the milk concentration (26,27). 
PBPK Modeling of the Transfer
of Chemicals into Breast Milk
In addition to obtaining a qualitative under-
standing of the process by which infants are
exposed to potentially toxic chemicals, it is
important to quantitatively evaluate the risk
of previous maternal exposure and predict
possible infant doses that could result from
inadvertent maternal exposures via occupa-
tion or environment. This was first accom-
plished with classical pharmacokinetic
models; for example, Wilson et al. (5) used
a three-compartment open model to
describe the distribution and elimination of
drugs in breast-feeding women. The infant
dose was calculated by multiplying the
maternal plasma drug concentration by the
milk:plasma ratio (M:P) and the volume of
ingested milk. However, Wilson et al. (28)
drew attention to the signiﬁcant uncertainty
in this approach resulting from the fact that
the concentrations of the drug in the
mother’s plasma and milk are time depen-
dent and not always concurrent, which
could lead to decreased accuracy in pre-
dicted infant exposure.
Recently, physiologically based pharma-
cokinetic (PBPK) models have been used to
help quantify the transfer of a chemical to
the infant during breast-feeding. These mod-
els of lactational transfer make it possible to
account for time-dependent changes in
maternal physiology and transfer kinetics, as
well as chemical characteristics, in order to
more accurately predict infant exposure.
Shelly et al. (29) were one of the first
research teams to employ PBPK modeling
techniques in the development of a quantita-
tive estimate of exposure to nursing infants
from contaminated breast milk. These inves-
tigators used the model as a tool to describe
the effect of the blood–air partition coeffi-
cient on the predicted distribution and
potential delivered dose of inhaled volatile
chemicals to infants via the breast milk.
Although this work did not actually simulate
laboratory data, it did provide the basis for
estimating the impact of a chemical’s lipid
afﬁnity on distribution to breast milk. 
The use of PBPK modeling is also beneﬁ-
cial in reproducing changing exposure pat-
terns (e.g., chronic vs. acute) and varied
routes of exposure (e.g., inhalation vs. intra-
venous dosing). For example, Fisher et al.
(30) developed a physiologic rat model for
transfer of trichloroethylene from exposed
dams to nursing neonates. Using this model,
Fisher et al. (30) successfully described
kinetic data for both TCE and its metabolite,
trichloroacetic acid, in the dam and pup after
both inhalation and intravenous exposures. 
An additional benefit of using PBPK
modeling is the ability to use epidemiologic
and animal data to predict human dose–
response relationships. Human dosing stud-
ies during lactation are rarely available
because of ethical issues. Therefore, in many
cases, only epidemiologic and animal studies
are available for use in risk assessment. It is
possible to build a PBPK model based on
known changes in physiology during lacta-
tion and chemical kinetics for exposures not
associated with lactation. Thus, relatively
few data are required to develop the chemi-
cal kinetic parameters unique to lactation
(e.g., uptake in the mammary gland) and to
validate dose–response relationships from
effects associated with chemical exposures.
Byczkowski and Fisher (31,32) developed
a PBPK model for the lactational transfer of
tetrachloroethylene (PCE) in the rat. The
authors then scaled the validated rat model
up to the human and tested against data in
nonlactating men and women exposed to
PCE occupationally and after a single dose.
Byczkowski and Fisher (31,32) used this
model to estimate the extent of an accidental
acute exposure of a lactating woman to PCE
from maternal blood and milk PCE concen-
trations measured at approximately 3 and 26
hr postexposure. An equation obtained from
the U.S. Environmental Protection Agency
(EPA) (33) was used to link dose predictions
from the PBPK model to cancer risk esti-
mates resulting from PCE to predict the
neonatal risk at doses that were not measured
experimentally.
In the case of MeHg, two human data
sets are available in which maternal and infant
tissues were measured after ingestion of
MeHg-contaminated food (34,35). Due to
the nature of the studies, it was not possible
to measure the amount ingested to determine
administered dose. However, Byczkowski and
Lipscomb (36) were able to develop a PBPK
model for the lactating woman and nursing
infant based on a previous model for the preg-
nant human (37). By accounting for the dif-
ferences in physiology (38) and using the
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Figure 1. Changes in fat content of human milk
during lactation in a group of mothers carrying
their infants through normal pregnancy. Data from
Bitman et al. (17).
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Figure 2. Effects of protein (A) and fat (triglyceride) (B) content on the human milk:air partition coefﬁcient
for benzene. Each point is one milk sample; all samples are from one human subject. Data from Greene et
al. (20).
40
35
30
25
20
15
10
5
M
i
l
k
:
a
i
r
 
p
a
r
t
i
t
i
o
n
 
c
o
e
f
f
i
c
i
e
n
t
0
Protein (g/L)
01 0
Triglycerides (g/L)
51 0 1 5 2 0
40
35
30
25
20
15
10
5
20 30 40 50 60
A B
M
i
l
k
:
a
i
r
 
p
a
r
t
i
t
i
o
n
 
c
o
e
f
f
i
c
i
e
n
t
r 2 = 0.15 r 2 = 0.87description of kinetics from the pregnant
human model, Byczkowski and Lipscomb
(36) used the lactation model to describe
MeHg distribution from real-world exposures
measured in maternal hair and milk, as well as
infant blood, at both toxic and environmen-
tally relevant doses. Additionally, they used
the model to reconstruct the level and timing
of MeHg exposure from tissue measurements
taken after the episode. 
Predicting transfer of inorganic chemicals
via breast milk presents unique challenges
that were not previously encountered in
working with organic chemicals. Although
the levels of organic compounds passed into
the milk are based primarily on partitioning,
both ionic compounds and metals are usually
transferred into the mammary tissue via some
type of transport process. Active transport
can introduce higher concentrations into the
milk than would be expected if only classical
partitioning or binding were taken into con-
sideration. For example, milk:plasma ratios
>1   have been reported for metals such as
mercury (M:P = 3) (39) and cadmium (M:P
= 2 to 6) (40) and for essential minerals such
as iodide (M:P = 14–44) (41). Active trans-
port mechanisms effectively concentrate nec-
essary nutrients that are available in low
concentrations from traditional food sources.
However, when toxic chemicals are intro-
duced in high levels through occupational or
environmental exposure, they can have an
adverse effect on postnatal development. 
Manganese, for example, is an essential
nutrient and a trace element. It is usually
consumed in low levels by the mother and is
therefore concentrated in milk in order to
deliver the necessary levels to the infant (42).
However, high levels of Mn can cause neu-
rologic effects. Interestingly, maternal milk
has been found to contain less Mn (~5
mg/L) than commercial soy-based formulas
(several hundred milligrams per liter), sug-
gesting that breast-feeding would result in a
lower infant exposure to Mn (43). 
PBPK Model for Perchlorate-
Induced Inhibition of Thyroid
Iodide Uptake
Perchlorate, the soluble anion of the solid
rocket fuel ammonium perchlorate, is a thy-
roid iodide uptake inhibitor known to be
present in the drinking water sources of sev-
eral states (44). Because ClO4
– has a similar
size and shape to that of iodide, it is able to
bind to sodium–iodide symporter (NIS) at
the basolateral membrane of the thyroid
epithelium, thereby reducing the amount of
iodide available for hormone synthesis. The
presence of NIS in the mammary gland also
allows inhibition of iodide uptake, as well as
the accumulation and transfer of the ClO4
–
anion, in the milk. Major health concerns
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Figure 3. Model schematic for the lactational transfer of perchlorate and iodide from the mother to the
neonate. Abbreviations: CA, arterial blood concentration; Ktrans, suckling rate; pDose, drinking water
dose; QC, cardiac output; QF, blood ﬂow total; RBCs, red blood cells. 
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Figure 4. Perchlorate concentration in maternal milk (A) and male neonatal serum (B) after exposing lactat-
ing rats to 0.01, 0.1, 1.0, or 10.0 mg/kg/day ClO4
– in drinking water. Solid lines indicate model prediction and
cross-bars indicate mean ± SD of the data. Daily perchlorate dosing via maternal drinking water began
during gestation and continued until the time of euthanization on either the 5th or 10th day of lactation.
Data from Yu et al. (48).
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roid hormones, which are synthesized from
iodide, are necessary for normal physical and
mental development during the period of
rapid growth in late gestation and early
infancy. Hypothyroidism and iodide defi-
ciency are known to cause neurodevelopmen-
tal effects during this critical period (3,45).
To quantify risk to the developing infant
from maternal ClO4
– exposure, we developed
a PBPK model for perchlorate and iodide in
the lactating and neonatal rat, focusing on
the transfer of anions through milk and
ClO4
–-induced inhibition of iodide in the
thyroid as the measures of internal dose. 
The perchlorate and iodide rat lactation
models have compartments for the thyroid,
stomach, skin, kidney, liver, fat, and plasma
in the lactating dam and suckling neonate,
and the mammary gland and milk in the
dam. Tissues with active uptake include the
mammary gland, milk, stomach, skin, and
thyroid, and were described with multiple
compartments and Michealis-Menten kinet-
ics to simulate saturable transport. We
obtained physiologic and kinetic parameters
from the literature and from experiments.
We obtained systemic clearance, milk trans-
fer, and Michealis-Menten uptake parame-
ters by ﬁtting simulations to intralaboratory
experimental data in the lactating and
neonatal rat. The schematic of the lactation
model for the rat and human is shown in
Figure 3. A more complete description of
the PBPK model for transfer of perchlorate
in the lactating and neonatal rat has been
published elsewhere (46).
The rat lactation model successfully
describes the nonlinear behavior of ClO4
– in
the maternal thyroid and milk, as well as
transfer to the neonate (maternal milk and
neonatal serum; Figure 4). Iodide is also well
described in the lactating and neonatal rat
(maternal mammary gland and neonatal
plasma; Figure 5). The model-predicted
inhibition of iodide uptake in the maternal
rat thyroid via exposure to ClO4
– (shown
against our measured data; Figure 6). 
Although the primary concern is obvi-
ously the human effect, few data exist for
human perchlorate exposure, and no quanti-
tative ClO4
– data in the lactating mother
have been reported. Therefore, we first
developed and validated PBPK models for
both ClO4
– and I– in the rat and then
extrapolated the models to the human by
adjusting physiologic parameters. We scaled
chemical-speciﬁc kinetic parameters allomet-
rically from the rat lactation model, except
for those parameters for which species differ-
ences are known to exist. We calculated
kinetic parameters with significant species
differences (e.g., follicular uptake and col-
loidal storage of iodide in the thyroid, ClO4
–
binding to plasma proteins) between the lac-
tating human and the lactating rat using the
ratio of male rat:human parameters derived
from available data and the concurrently
developed male rat and nonpregnant human
models (data not shown).
We then validated the human model
against available radioiodide data in lactating
women and nursing infants. Figure 7 shows
model-predicted iodide in human milk after
a single intravenous dose of radioiodide
(131I–) to the mother using the data of
Dydek and Blue (47). Because only iodide
data were available for model validation, we
based extrapolation to human perchlorate
kinetics on the assumption that if the model
is able to describe both anions in the rat and
is successfully extrapolated to human iodide
exposure, then the model should also pro-
duce a reasonable estimate of predicted
ClO4
– kinetics in the human.
Summary
The advantage of using PBPK models for
predicting perchlorate kinetics and iodide
inhibition, as well as for other chemicals, is
increased confidence in predicted kinetics
under different exposure scenarios and in
different species. Changes in physiology
through most life processes (e.g., lactation),
as well as mechanistic knowledge (e.g., bind-
ing or transport processes), can be incorpo-
rated quantitatively into the calculation of
chemical kinetics. As a result, using these
models, we are able to integrate data from a
variety of sources, both animal and human,
to improve both the accuracy and reliability
of the resulting risk assessment. 
In the case of perchlorate and iodide, we
incorporated kinetic, mechanistic, chemical,
and physiologic information into the model
to quantify thyroidal inhibition of iodide
uptake in the mother and chemical dose to
the neonate in the absence of human data. In
the case of MeHg, Byczkowski and Lipscomb
(36) used a PBPK model to reconstruct
maternal exposures associated with infant
toxicity. Modeling of lactational transfer of
lipophilic chemicals has also been used to pre-
dict exposures to nursing infants compared to
maternal exposure as a function of chemical
properties (28). These examples demonstrate
the potential value of PBPK modeling for
predicting the risk associated with breast-
feeding from a quantitative perspective.
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Figure 7. 131I– concentration in human milk of one
mother after an oral dose of 77.4 ng 131I–. Data
from Dydek and Blue (47). Solid lines indicate
model prediction and points indicate individual
data points. The single intravenous dose of 131I–
was given at 3,240 hr (fourth month of lactation).
Figure 6. 131I– concentration in maternal thyroid of
rats after an intravenous (iv) dose of 1.87 ng/kg 125I–
to the dam, with or without an iv dose of 1.0 mg/kg
ClO4
– 2 hr later. Solid lines indicate model predic-
tion and cross-bars indicate mean ± SD of the data.
The iv doses of 131I– and ClO4
– were given on the
10th day of lactation. Data from Mahle et al. (49).
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Figure 5. 131I– concentration in maternal mammary gland (A) and male neonatal serum (B) after exposing
lactating rats to 2.19 ng/kg 125I– via intravenous injection. Solid lines indicate model prediction and cross-
bars indicate mean ± SD of the data. Daily perchlorate dosing began via maternal drinking water during
gestation and continued until the time of euthanization on either the 5th or 10th day of lactation. Data from
Mahle et al. (49).
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